Start Disrupting

Entrepreneurship, technology and integrating all your skills with Gary Warren, President and CEO of ivWatch

July 07, 2021 Virginia Tech Corporate Research Center Season 1 Episode 13
Start Disrupting
Entrepreneurship, technology and integrating all your skills with Gary Warren, President and CEO of ivWatch
Show Notes

Gary Warren currently serves as president and CEO of ivWatch and has championed the development of non-invasive biosensors that fulfill a huge patient safety need in healthcare. Starting ivWatch in 2010, Gary assembled a team of leading scientists, clinicians, hospitals, and investors to solve a common drug delivery problem of IV infiltration and extravasation. Gary has guided ivWatch through multiple FDA and ISO clearances for this breakthrough technology with ivWatch products now being sold on the international market. 

Gary has a multidisciplinary background with a 14-year career as a research scientist at NASA in aerospace and computational fluid dynamics. He then left NASA to start a successful Internet infrastructure company in the mid-1990’s and served as CEO until it’s sale to Symantec in 1999. At Symantec, Gary served as a senior vice president and oversaw advanced technologies, mergers and acquisitions and gateway software products. He also served as a member of the senior executive staff. After Symantec, Gary served as CEO for a venture-backed mobile platform company as smartphones were beginning to emerge as a market. After the sale of this company to Oracle, Gary worked for various venture capital companies doing financial analysis and due diligence which brought him to the work being done on IV infiltrations under a National Institutes of Health grant. Bringing over the core engineering talent and founding the company, Gary has grown ivWatch to an award-winning brand in healthcare that is changing the standard of care for IV therapy.

About ivWatch, LLC 
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.